27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.
Our results show that MA enrollees in PR have six percentage points higher ADRD rates than their US counterparts. 2 key findings →
Participants: 123,609 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Overall, 3.3% of beneficiaries switched to MA annually. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Among the 1,035 patients in our dataset, 176 (17%) had a dementia diagnosis. 5 key findings →
Participants: 1,035 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The number of individuals with anorexia ranged from 317,964 to 328,977 per year, a mean annual prevalence rate of 1.1%. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Diabetes care guidelines recommend more relaxed glycemic targets for patients with specific chronic conditions because they are thought to have an increased risk of hypoglycemia, limited life expectancy, and/or high clinical complexity. 3 key findings →
Participants: 216,839 Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
The Mississippi Healthy Aging Data Report (see healthyagingdatareports.org) has helped policymakers, service providers, and advocates better understand the status of healthy aging in Mississippi. 5 key findings →
Participants: 663,581 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
There is a consistent difference between Appalachian and non‐Appalachian counties, with Appalachian counties having relatively higher ADRD prevalence (in the range of 2.0‐3.0% times higher) than non‐Appalachian counties. 4 key findings →
Participants: 255 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Cardiovascular diseases (CVDs) remain the main cause of mortality and are generally among the leading causes of morbidity worldwide, thus placing an immense burden on health care. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Over a three-month period, MT+CST was more effective than CST alone in improving cognitive function but was not cost-effective due to higher initial costs, including setup and equipment. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Anti-amyloid monoclonal antibodies (lecanemab and donanemab) represent the first disease-modifying therapies for early symptomatic Alzheimer's disease (AD)- Italy's National Health Service (SSN) must determine whether to include these therapies within Essential Levels of Care (LEA), requiring reimbursement across all regions. 5 key findings →
Participants: 42,000 Evidence: low
Full summary, score breakdown and related studies → Original source
Recent evidence suggests that ocular testing holds promise as a non-invasive and cost-effective method for the early detection of Alzheimer's disease (AD). 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Spending at end of life (EOL) accounts for a large and growing share of healthcare expenditures in the US, and often reflects aggressive care with questionable value for dying patients. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
There are many studies of medical costs in late life in general, but nursing home residents' needs and the costs of external medical services and interventions outside of nursing home services are less well described. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Home-based medical care (HBMC) delivers physician or advanced practice provider-led medical services for patients in private residences and domiciliary settings (eg, assisted living facilities, group/boarding homes). 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Hospitalized patients with dementia transitioning to post-acute care may be particularly vulnerable to changes in post-acute care utilization driven by payment reforms; however, use of post-acute care in this population is incompletely understood. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Each year, the French independent bulletin Prescrire publishes a list of medicines, "Drugs to avoid", that should not be used in clinical practice as their risk-to-benefit ratio is unfavourable. 1 key finding →
Participants: 50,000 Evidence: low
Full summary, score breakdown and related studies → Original source
Patients with multiple serious conditions account for a high proportion of health care spending. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
'We DECide' had a positive influence on advance care planning policy. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Mechanisms of epigenetic regulation, including DNA methylation, chromatin remodeling, and histone post-translational modifications, are involved in multiple aspects of neuronal function and development. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Cerebral blood flow (CBF) regulation is essential for normal brain function. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Care of individuals with Alzheimer's Disease and Related Dementias (ADRD) poses special challenges. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Dementia substantially increases lifetime costs of care. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Faced with increasing demands on demonstrating cost effectiveness, pharmaceutical companies are required to conduct pharmacoeconomic evaluations throughout the drug development programme. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Due to the rapid increase of the number in people with dementia, social costs of dementia are also expected to rise. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
This article examines transitions between the community and nursing homes among the private pay and the Medicaid eligible older (65+) persons. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
10 of the 705 studies in this tag, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 10. The same 10 appear here every time.
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →